Renal medullary carcinoma: Molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy

BJU International

Volumn 106, Issue 1, 2010, Pages 62-65

  Schaeffer, Edward M ^a   Guzzo, Thomas J ^a   Furge, Kyle A ^a   Netto, George ^a   Westphal, Michael ^a   Dykema, Karl ^a   Yang, Ximing ^a   Zhou, Ming ^a   Teh, Bin Tean ^a   Pavlovich, Christian P ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Chemotherapy; Renal medullary carcinoma

Indexed keywords

BORTEZOMIB; CARBOPLATIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; GEMCITABINE; PACLITAXEL;

ADULT; ARTERY THROMBOSIS; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; DNA REPAIR; ENZYME INHIBITION; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LUNG METASTASIS; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL MEDULLARY CARCINOMA; SALVAGE THERAPY; THROMBECTOMY; TREATMENT RESPONSE; UROGENITAL TRACT CANCER;

ADULT; ANEMIA, SICKLE CELL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, MEDULLARY; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ENZYME INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; NEPHRECTOMY; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953206989     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09139.x     Document Type: Article

References (16)

1. Davis CJ, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 1995 19 : 1 11
2. Sathyamoorthy K, Teo A, Atallah M. Renal medullary carcinoma in a patient with sickle-cell disease. Nat Clin Pract Urol 2006 3 : 279 283
3. Simpson L, He X, Pins M et al. Renal medullary carcinoma and ABL gene amplification. J Urol 2005 173 : 1883 8
4. Yang XJ, Sugimura J, Tretiakova MS et al. Gene expression profiling of renal medullary carcinoma: potential clinical relevance. Cancer 2004 100 : 976 985
5. Albadine R, Wang W, Brownlee NA et al. Topoisomerase II alpha status in renal medullary carcinoma: immune-expression and gene copy alterations of a potential target of therapy. J Urol 2009 182 : 735 740
6. Furge KA, Chen J, Koeman J et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res 2007 67 : 3171 3176
7. Chi JT, Wang Z, Nuyten DS et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006 3 : e47
8. Hakimi AA, Koi PT, Mihoua PM et al. Renal medullary carcinoma: the Bronx experience. Urology 2007 70 : 878 882
9. Khan A, Thomas N, Costello B et al. Renal medullary carcinoma: sonographic, computed tomography, magnetic resonance and angiographic findings. Eur J Radiol 2000 35 : 1 7
10. Selby DM, Simon C, Foley JP, Thompson IM, Baddour RT. Renal medullary carcinoma: can early diagnosis lead to long-term survival? J Urol 2000 163 : 1238
11. Rathmell WK, Monk JP. High-dose intensity MVAC for advanced renal medullary carcinoma: report of three cases and literature review. Urology 2008 72 : 659 663
12. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002 20 : 2376 2381
13. Strouse JJ, Spevak M, Mack AK, Arceci RJ, Small D, Loeb DM. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer 2005 44 : 407 411
14. Swartz MA, Karth J, Schneider DT, Rodriquez R, Beckwith JB, Perlman EJ. Renal medullary carcinoma: clinical pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology 2002 60 : 1083 1089
15. Nitiss JL. Targeting DNA Topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009 9 : 338 350
16. Ronnen EA, Kondagunta GV, Motzer RJ. Medullary renal cell carcinoma and response to therapy with bortezomib. J Clin Oncol 2006 24 : e14